Despite evidence of systemic complement activation and activation of coagulation in cancer patient cohorts with and without COVID-19 and elevated D-dimers, C1 INH and FH levels remained within published reference ranges (Quidel MicroVue C1-Inhibitor Plus EIA. The gene discussed is SERPING1; the disease is COVID-19.